Patient‐reported outcomes
pain
In patients randomized to spesolimab, continuous improvement was seen in pain VAS, FACIT‐Fatigue, DLQI, and PSS over 8 weeks, with some plateauing of the effect between Weeks 8 and 12 (Figure Median absolute changes from baseline over time in pain VAS (a), FACIT‐fatigue (b), DLQI (c), and PSS (d). Data are shown for patients initially randomized to receive spesolimab who received up to two doses of spesolimab: Day 1 (